HIV Infections Clinical Trial
Official title:
Phase II Study of Intravenous Recombinant Humanized Anti-Vascular Endothelial Cell Growth Factor Antibody (Bevacizumab) in Classical (HIV-Negative) and in AIDS-Associated Kaposi's Sarcoma
This study will examine the safety and effectiveness of the experimental drug bevacizumab
for treating both non-acquired immune deficiency syndrome (AIDS) and AIDS-associated
Kaposi's sarcoma (KS). KS tumors depend on the formation of new blood vessels for their
growth. Bevacizumab is an antibody to a protein called vascular endothelial growth factor
(VEGF) that is produced by the body and is involved in blood vessel growth. Bevacizumab may
block the action of VEGF, and thus help shrink KS lesions.
Patients 18 years of age and older with Kaposi's sarcoma that is restricted to the skin and
is not life threatening may be eligible for this study. Candidates will be screened with a
medical history and physical examination, blood and urine tests, electrocardiogram (EKG),
chest x-ray, and, if needed, imaging studies to evaluate internal tumors.
Participants will receive bevacizumab intravenously (by vein) once a week for 2 weeks and
then every 3 weeks at the National Institutes of Health (NIH) Clinical Center. The first
infusion takes about 90 minutes, the second takes about 60 minutes, and subsequent infusions
take about 30 minutes. Infusions may take longer, however, if the drug is better tolerated
at a slower infusion rate. Patients will be evaluated with the following tests and
procedures:
- Physical examination, assessment of drug side effects, measurement of KS lesions, and
photographs of lesions once a week for the first 6 weeks of therapy, and then every 3
weeks.
- cluster of differentiation 4 (CD4) cell counts and human immunodeficiency virus (HIV)
viral load in HIV-positive patients every 12 weeks.
- Biopsies of lesions: upon entering the study, at week 12, and at the time of a response
of the tumor to therapy or at the end of treatment, if treatment ends at week 18 or
later.
- Additional biopsies, if requested. (Additional biopsies are not required.)
- Other procedures, such as computed tomography (CT) or magnetic resonance imaging (MRI)
scans, if medically indicated.
Patients may continue bevacizumab therapy indefinitely if they are benefiting from it, as
long as they have no substantial toxicity or other conditions that would cause them to stop
receiving it and the protocol remains open.
BACKGROUND:
This is a phase II study to determine the activity of bevacizumab, a putative antiangiogenic
agent, in Kaposi's sarcoma (KS). Bevacizumab is a humanized recombinant antibody to vascular
endothelial cell growth factor (VEGF), an important cytokine in the pathogenesis of KS.
OBJECTIVES:
To assess the antitumor effect of bevacizumab 15 mg/kg administered intravenously once every
three weeks in patients with human immunodeficiency virus (HIV)-associated Kaposi's sarcoma
(KS). Other objectives include assessment of the antitumor effect of bevacizumab 15 mg/kg
administered intravenously once every three weeks in patients with classical KS; assessment
of the toxicity profile of bevacizumab in HIV-infected and HIV-negative patients with KS;
exploration in a preliminary fashion effect of bevacizumab on KS progression free survival;
and study of a number of biochemical parameters, including stromal cell-derived factor-1
(SDF-1) expression in KS lesions; human herpes virus-8 (HHV-8) viral load in peripheral
blood mononuclear cells; serum vascular endothelial growth factor (VEGF) levels over the
course of treatment; and changes in viral interleukin 6 (IL-6) levels over the course of
treatment.
ELIGIBILITY:
Key eligibility parameters include HIV-associated or classical Kaposi's sarcoma, age greater
than or equal to 18 years, and life expectancy greater than 6 months. Patients with HIV
infection must have either KS progression on a regimen of highly active antiretroviral
therapy (HAART) for at least one month, or no KS regression while on an optimized regimen of
HAART for 4 months or longer.
DESIGN:
Patients will be sequentially enrolled, administered a loading dose of 15 mg/kg bevacizumab
intravenously on day 1, and then administered 15 mg/kg bevacizumab intravenously every 3
weeks beginning one week after the loading dose. The drug will be temporarily discontinued
for toxicity, intercurrent major surgical procedures, or other factors that would pose a
safety concern. Patients will undergo a biopsy of a KS lesion at entry, on cycle 4, day 21,
and at the time of a formal response or when the patient stops treatment. Patients will
undergo a number of other tests as well, including blood tests and non-invasive imaging
studies of KS lesions.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |